Literature DB >> 9642494

Flow cytometric analysis of lymphocyte subsets in migraine patients during and outside of an acute headache attack.

A D Mosnaim1, H Kulaga, A J Adams, M E Wolf, J Puente, F Freitag, S Diamond.   

Abstract

We have conducted flow cytometric studies of two subsets of lymphocyte markers in groups of migraineurs during (n = 12; group B) and outside (n = 10; group C) of a migraine without aura attack (total n = 22; group A), including a group of patients tested in both of these phases (n = 5; group D), and compared these results with those obtained from a population of age-comparable, sex- and race-matched healthy volunteers (n = 12; group E). Comparison of the first set of lymphocytes (CD3+CD16 + 56+, CD3-CD16 + 56+, CD3-CD19+, CD3+CD19+, and CD3+HLA - DR+) between the patients in group A and the controls (group E) showed differences, reflecting greater group A percentages of CD3+CD16 + CD56+ and CD3-CD19+ lymphocytes. Furthermore, these differences reached statistical significance only for the CD3+CD16 + CD56+ lymphocytes, and then solely for the patients in group C (Scheffe's test, p < 0.05). Paired analysis of the above lymphocyte markers for subjects in group D failed to show significant differences between patients when they were having and not having a migraine attack, raising the possibility that results from a larger study could show meaningful increases in percentages of CD3+CD16 + CD56+ lymphocytes as one of the immune parameters useful for differentiating migraineurs from controls. Comparison of a second set of lymphocyte markers (CD19+CD5+, CD20+CD72-, CD20-CD72+, CD20+CD72+) among either the different groups of patients or between the patients and controls failed, however, to show statistically significant differences, emphasizing the apparent specificity of the findings described above for CD3+CD16 + CD56+ lymphocytes. Our results, albeit of a preliminary nature, suggest the occurrence of significant, differential changes in lymphocyte subset immunophenotyping between groups of pain-free migraineurs and patients during an acute migraine episode or controls. Corroboration of these findings may prove useful in clinical laboratory practice to identify changes in immunological parameters specifically associated with migraineurs, and help towards a better understanding of the etiology and pathophysiology of this condition.

Entities:  

Mesh:

Year:  1998        PMID: 9642494     DOI: 10.1046/j.1468-2982.1998.1804197.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  5 in total

1.  Lymphocyte subsets in pediatric migraine.

Authors:  Aron Cseh; Kristof Mark Farkas; Laszlo Derzbach; Katalin Muller; Barna Vasarhelyi; Balazs Szalay; Andras Treszl; Viktor Farkas
Journal:  Neurol Sci       Date:  2012-10-16       Impact factor: 3.307

2.  Platelet-leukocyte interaction and platelet activation in migraine: a link to ischemic stroke?

Authors:  J A Zeller; K Frahm; R Baron; R Stingele; G Deuschl
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

Review 3.  Biological correlates of migraine and cluster headaches: an overview of their potential use in diagnosis and treatment.

Authors:  Aron D Mosnaim; Javier Puente; Marion E Wolf
Journal:  Pragmat Obs Res       Date:  2010-12-03

4.  Increased Serum CD14 Level Is Associated with Depletion of TNF-α in Monocytes in Migraine Patients during Interictal Period.

Authors:  Slawomir Michalak; Alicja Kalinowska-Lyszczarz; Danuta Wegrzyn; Adam Niezgoda; Jacek Losy; Krystyna Osztynowicz; Wojciech Kozubski
Journal:  Int J Mol Sci       Date:  2017-02-13       Impact factor: 5.923

Review 5.  Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms.

Authors:  Leonardo Biscetti; Gioacchino De Vanna; Elena Cresta; Ilenia Corbelli; Lorenzo Gaetani; Letizia Cupini; Paolo Calabresi; Paola Sarchielli
Journal:  J Neuroinflammation       Date:  2021-11-08       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.